CCSG Developmental Funds are important to allow Roswell Park Comprehensive Cancer Center leadership opportunities to pursue new initiatives that align with the strategic plan. The funds provide support for strategic priorities that further the cancer center mission. CCSG Developmental Funds are usually leveraged alongside institutional and philanthropic funds to support key faculty recruitment, shared resource development and innovative pilot projects. During the current project period, CCSG developmental funds supported 9 new faculty investigators; significant investment in shared resources to develop new techniques and to enhance new utilization of shared resource services; and 24 pilot projects. These efforts have catalyzed collaborative efforts within and across CCSG Programs that have yielded an impressive overall return on investment, measured as publications and grants awarded as a result of the pilot research. The CCSG/ Roswell Park Alliance Foundation Scientific Advisory Committee process administers and oversees allocation of cancer center pilot project funding. Meritorious, high impact, high risk projects are considered through this funding mechanism. This process has worked well to ensure internal, peer-review of the applications. Candace Johnson, CCSG PI ultimately manages the allocation process and ensures requests are in line with the Strategic Plan and cancer center priorities. CCSG Developmental Funds add value by providing a flexible, dynamic source of funding that further the overall mission and priorities of the center. Developmental Funds provide the opportunity to fund innovative pilot projects, support new shared resources or enhance existing shared resources with new technologies, and recruit key faculty in alignment with the strategic plan. During the next grant period, funds will support recruitment, shared resources: ? Recruitments: The Center will recruit 2 key investigators per year. Developmental funds of $300,000 a year will be used to support new investigators in each of the CCSG programs over project period. ? Shared Resources: The Center will use $100,000 a year to help develop new Shared Resources such as Community Engagement Shared Resource, invest funds in new technologies to enhance existing shared resources. ? Pilot Grants: Grants will be awarded to individual investigators through the Scientific Advisory Committee (SAC) process, to each research program, and for Team Science. Strategic emphasis will be placed on funding proposals that are collaborative and interdisciplinary in order to encourage large multi-investigator initiatives and grants. Developmental funds of $200,000 a year will be used to support pilot projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-43
Application #
9923590
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
43
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :
Zhang, Dingxiao; Tang, Dean G; Rycaj, Kiera (2018) Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol 52:94-106
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Tubbs, Anthony; Sridharan, Sriram; van Wietmarschen, Niek et al. (2018) Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork Collapse. Cell 174:1127-1142.e19

Showing the most recent 10 out of 1555 publications